Direct-acting antiviral treatment for HIV/HCV patients in safety net settings: patient and provider preferences

References

• Attar, B. M., & Van Thiel, D. H. (2016). Hepatitis C virus: A time for decisions. Who should be treated and when? World Journal of Gastrointestinal Pharmacology and Therapeutics, 7, 33–40. doi: 10.4292/wjgpt.v7.i1.33
   PubMedGoogle Scholar
• Bidell, M. R., McLaughlin, M., Faragon, J., Morse, C., & Patel, N. (2016). Desirable characteristics of hepatitis C treatment regimens: A review of what we have and what we need. Infectious Diseases and Therapy, 5, 299–312. doi: 10.1007/s40121-016-0118-x
   PubMed Web of Science ®Google Scholar
• Bova, C., Ogawa, L. F., & Sullivan-Bolyai, S. (2010). Hepatitis C treatment experiences and decision making among patients living with HIV infection. Journal of the Association of Nurses in AIDS Care, 21, 63–74. doi: 10.1016/j.jana.2009.07.009
   PubMed Web of Science ®Google Scholar
• Cachay, E. R., Wyles, D., Hill, L., Ballard, C., Torriani, F., Colwell, B. … Mathews, C. W. (2015). The impact of direct-acting antivirals in the hepatitis C-sustained viral response in human immunodeficiency virus-infected patients with ongoing barriers to care. Open Forum Infectious Diseases, 2, 1–10. doi: 10.1093/ofid/ofv133.1225
   Google Scholar
• Chahal, H. S., Marseille, E. A., Tice, J. A., Pearson, S. D., Ollendorf, D. A., Fox, R. K., & Kahn, J. G. (2016). Cost-effectiveness of early treatment of hepatitis C virus genotype 1 by stage of liver fibrosis in a US treatment-naïve population. JAMA Internal Medicine, 176, 65–73. doi: 10.1001/jamainternmed.2015.6011
   PubMed Web of Science ®Google Scholar
• Chastain, C. A., Beekmann, S. E., Wallender, E. K., Hulgan, T., Stapleton, J. T., & Polgreen, P. M. (2015). Hepatitis C management and the infectious diseases physician: A survey of current and anticipated practice patterns. Clinical Infectious Diseases, 61, 792–794. doi: 10.1093/cid/civ384
   PubMed Web of Science ®Google Scholar
• Cuypers, L., Ceccherini-Silberstein, F., Van Laethem, K., Li, G., Vandamme, A. M., & Rockstroh, J. K. (2016). Impact of HCV genotype on treatment regimens and drug resistance: A snapshot in time. Reviews in Medical Virology, 26, 408–434. doi: 10.1002/rmv.1895
   PubMed Web of Science ®Google Scholar
• Del Bello, D., Ita Nagy, F., Hand, J., Khedemi, R., Lecluse-Barth, J., Dieterich, D., & Piroth, L. (2015). Direct-acting antiviral-based therapy for chronic hepatitis C virus in HIV-infected patients. Current Opinion in HIV and AIDS, 10, 337–347. doi: 10.1097/COH.0000000000000182
   PubMed Web of Science ®Google Scholar
• Duberg, A. S., Blach, S., Falconer, K., Kåberg, M., Razavi, H., & Aleman, S. (2015). The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies. Scandanavian Journal of Gastroenterology, 50, 233–244. doi: 10.3109/00365521.2014.990505
   PubMed Web of Science ®Google Scholar
• Falade-Nwulia, O., Mehta, S. H., Lasola, J., Latkin, C., Niculescu, A., O’Connor, C., … Thomas, D. L. (2016). Public health clinic-based hepatitis C testing and linkage to care in Baltimore. Journal of Viral Hepatitis, 23, 366–374. doi: 10.1111/jvh.12507
   PubMed Web of Science ®Google Scholar
• Feeney, E. R., Chung, R. T., & Yazdanpanah, Y. (2015). Current guidelines and prioritizing treatment of hepatitis C virus in HIV-infected patients. Current Opinion in HIV and AIDS, 10, 323–329. doi: 10.1097/COH.0000000000000178
   PubMed Web of Science ®Google Scholar
• Fleming, C. A., Tumilty, S., Murray, J. E., & Nunes, D. (2005). Challenges in the treatment of patients coinfected with HIV and hepatitis C virus: Need for team care. Clinical Infectious Diseases, 40(Suppl 5), S349–S354. doi: 10.1086/427452
   PubMed Web of Science ®Google Scholar
• Fraenkel, L., Chodkowski, D., Lim, J., & Garcia-Tsao, G. (2010). Patients’ preferences for treatment of hepatitis C. Medical Decision Making, 30, 45–57. doi: 10.1177/0272989X09341588
   PubMed Web of Science ®Google Scholar
• Fraenkel, L., Lim, J., Garcia-Tsao, G., Reyna, V., & Monto, A. (2016). Examining hepatitis C virus treatment preference heterogeneity using segmentation analysis: Treat now or defer? Journal of Clinical Gastroenterology, 50, 252–257. doi: 10.1097/MCG.0000000000000380
   PubMed Web of Science ®Google Scholar
• Grebely, J., Robaeys, G., Bruggmann, P., Aghemo, A., Backmund, M., Bruneau, J., … Dore, G. J. (2015). Recommendations for the management of hepatitis C virus infection among people who inject drugs. International Journal of Drug Policy, 26, 1028–1038. doi: 10.1016/j.drugpo.2015.07.005
   PubMed Web of Science ®Google Scholar
• Hauber, A. B., Mohamed, A. F., Beam, C., Medjedovic, J., & Mauskopf, J. (2011). Patient preferences and assessment of likely adherence to hepatitis C virus treatment. Journal of Viral Hepatitis, 18, 619–627. doi: 10.1111/j.1365-2893.2010.01343.x
   PubMed Web of Science ®Google Scholar
• Kattakuzhy, S. M., Gross, C., Teferi, G., Jenkins, V., Emmanuel, B., Masur, H., & Kottilil, S. (2016). High efficacy of HCV treatment by primary care providers: The ASCEND study. Paper presented at the Conference on Retroviruses and Opportunistic Infections, Boston, MA.
   Google Scholar
• Kauf, T. L., Mohamed, A. F., Hauber, A. B., Fetzer, D., & Ahmad, A. (2012). Patients’ willingness to accept the risks and benefits of new treatments for chronic hepatitis C virus infection. The Patient, 5, 265–278.
   PubMedGoogle Scholar
• Kwong, J., & Epstein, R. (2015). Expanding capacity for hepatitis C treatment in the United States. Journal of the International Association of Providers of AIDS Care (JIAPAC), 14, 112–115. doi: 10.1177/2325957414560065
   PubMedGoogle Scholar
• Louviere, J. J., Flynn, T. N., & Marley, A. A. J. (2015). Best-worst scaling: Theory, methods and Applications. Cambridge, UK: Cambridge University Press.
   Google Scholar
• McGovern, B. H. (2012). Hepatitis C virus and the infectious disease physician: A perfect match. Clinical Infectious Diseases, 55, 414–417. doi: 10.1093/cid/cis378
   PubMed Web of Science ®Google Scholar
• Mühlbacher, A., & Bethge, S. (2016). First and foremost battle the virus: Eliciting patient prefererences in antiviral therapy for hepatitis C using a discrete choice experiment. Value in Health, 19, 776–787. doi: 10.1016/j.jval.2016.04.007
   PubMed Web of Science ®Google Scholar
• Mühlbacher, A., Bridges, J. F., Bethge, S., Dintsios, C. M., Schwalm, A., Gerber-Grote, A., & Nübling, M. (2017). Preferences for antiviral therapy of chronic hepatitis C: A discrete choice experiment. The European Journal of Health Economics, 18, 155–165. doi: 10.1007/s10198-016-0763-8
   PubMed Web of Science ®Google Scholar
• Pacou, M., Basso, F., Gore, C., Hass, B., Taieb, V., Cognet, M., & Pol, S. (2015). Patient and physician preferences for the treatment of chronic hepatitis C virus infections: Does the perspective matter? European Journal of Gastroenterology & Hepatology, 27, 1063–1068. doi: 10.1097/MEG.0000000000000410
   PubMed Web of Science ®Google Scholar
• Ramirez, G., Cabral, R., Patterson, M., Schoenbachler, B. T., Bedell, D., Smith, B. D., … Beckett, G. A. (2016). Early identification and linkage to care for people with chronic HBV and HCV infection: The HepTLC Initiative. Public Health Reports, 131(Suppl 2), 5–11. doi: 10.1177/00333549161310S202
   PubMedGoogle Scholar
• Rockstroh, J. K., & Hardy, W. D. (2016). Current treatment options for hepatitis C patients co-infected with HIV. Expert Review of Gastroenterology & Hepatology, 10, 689–695. doi: 10.1586/17474124.2016.1145545
   PubMed Web of Science ®Google Scholar
• Sawtooth Software, Inc. (2013). The MaxDiff software technical paper. Orem, UT: Author.
   Google Scholar
• Sawtooth Software, Inc. (2014). SSI web v8.3: Software for web interviewing and conjoint analysis. Orem, UT: Author.
   Google Scholar
• Shafran, S. D. (2015). HIV coinfected have similar SVR rates as HCV monoinfected with DAAs: It’s time to end segregation and integrate HIV patients into HCV trials. Clinical Infectious Diseases, 61, 1127–1134. doi: 10.1093/cid/civ438
   PubMed Web of Science ®Google Scholar
• Taylor, L. E., Swan, T., & Mayer, K. H. (2012). HIV coinfection with hepatitis C virus: Evolving epidemiology and treatment paradigms. Clinical Infectious Diseases, 55(Suppl 1), S33–S42. doi: 10.1093/cid/cis367
   PubMed Web of Science ®Google Scholar
• Treloar, C., Gray, R., & Brener, L. (2014). A piece of the jigsaw of primary care: Health professional perceptions of an integrated care model of hepatitis C management in the community. Journal of Primary Health Care, 6, 129–134. doi: 10.1071/HC14129
   PubMedGoogle Scholar
• Trooskin, S. B., Poceta, J., Towey, C. M., Yolken, A., Rose, J. S., Lugman, N. L., … Nunn, A. S. (2015). Results from a geographically focused, community-based HCV screening, linkage-to-care and patient navigation program. Journal of General Internal Medicine, 30, 950–957. doi: 10.1007/s11606-015-3209-6
   PubMed Web of Science ®Google Scholar
• U.S. Census Bureau. (2016, July 31). American factfinder. Retrieved from http://www.census.gov/quickfacts/table/AGE115210/06075.
   Google Scholar
• Wyles, D. L., Sulkowski, M. S., & Dieterich, D. (2016). Management of hepatitis C/HIV coinfection in the Era of highly effective hepatitis C virus direct-acting antiviral therapy: Table 1. Clinical Infectious Diseases, 63(Suppl 1), S3–S11. doi: 10.1093/cid/ciw219
   PubMedGoogle Scholar